AbbVie Inc. (NYSE:ABBV) Shares Purchased by G&S Capital LLC

G&S Capital LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 267.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 21,268 shares of the company’s stock after acquiring an additional 15,485 shares during the quarter. AbbVie comprises about 1.6% of G&S Capital LLC’s portfolio, making the stock its 14th largest position. G&S Capital LLC’s holdings in AbbVie were worth $3,779,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Avestar Capital LLC raised its position in AbbVie by 12.3% during the 4th quarter. Avestar Capital LLC now owns 12,866 shares of the company’s stock worth $2,286,000 after buying an additional 1,413 shares during the last quarter. MGB Wealth Management LLC increased its stake in shares of AbbVie by 3.8% in the fourth quarter. MGB Wealth Management LLC now owns 13,638 shares of the company’s stock worth $2,416,000 after acquiring an additional 493 shares during the period. Morris Financial Concepts Inc. raised its holdings in shares of AbbVie by 7.0% during the fourth quarter. Morris Financial Concepts Inc. now owns 2,736 shares of the company’s stock worth $486,000 after purchasing an additional 179 shares during the last quarter. Hemington Wealth Management lifted its position in AbbVie by 6.3% during the fourth quarter. Hemington Wealth Management now owns 2,536 shares of the company’s stock valued at $450,000 after purchasing an additional 150 shares during the period. Finally, McClarren Financial Advisors Inc. boosted its holdings in AbbVie by 8.9% in the fourth quarter. McClarren Financial Advisors Inc. now owns 770 shares of the company’s stock valued at $137,000 after purchasing an additional 63 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Piper Sandler Companies reiterated an “overweight” rating and set a $220.00 price objective on shares of AbbVie in a research note on Tuesday, December 17th. JPMorgan Chase & Co. reduced their price target on AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. Daiwa America cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 5th. Wells Fargo & Company increased their price target on shares of AbbVie from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, Bank of America restated a “neutral” rating and set a $191.00 target price on shares of AbbVie in a research report on Tuesday, December 10th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $208.35.

AbbVie Stock Performance

ABBV opened at $193.06 on Thursday. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32. The firm has a market capitalization of $341.16 billion, a PE ratio of 80.44, a PEG ratio of 1.53 and a beta of 0.58. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The firm’s 50-day moving average price is $178.24 and its 200 day moving average price is $185.91.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same period last year, the firm earned $2.79 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.